Search the Newsreel

PDT Partners discloses net short position in Abivax shares

PDT Partners has disclosed a 0.79% net short position in Abivax shares, which is just below the 1% threshold typically considered for major short stakes. This information was generated by Public Technologies (PUBT) using AI, based on content originally published by Abivax SA on …

Capital Fund Management discloses net short position in Abivax shares

Capital Fund Management has revealed a 0.5% net short position in Abivax shares. This news brief was generated by Public Technologies using AI and is based on original content published by Abivax SA on August 5, 2026. The information provided is for informational purposes …

Militia Capital Management LLC Makes New Investment in Abivax SA Sponsored ADR $ABVX

Militia Capital Management LLC has made a new investment in Abivax SA Sponsored ADR ($ABVX), purchasing 17,000 shares valued at approximately $1.89 million during the first quarter. Institutional investors collectively own 47.91% of Abivax, which holds a consensus "Moderate Buy" rating and an average …

Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Recommendation of "Moderate Buy" by Analysts

Abivax SA Sponsored ADR (NASDAQ:ABVX) has received an average "Moderate Buy" recommendation from analysts, with 13 out of 15 analysts rating the stock a buy. The average 12-month price target is $156.50, significantly above its current $124.92 share price. Recent positive analyst coverage includes …

Abivax SA Revenue Breakdown – TRADEGATE:2X1

The article provides a revenue breakdown for Abivax SA, listed on the Tradegate Exchange under the symbol 2X1. It highlights financial data, overview, statements, statistics, dividends, earnings, and segments, noting that the market is currently closed with no trades. The content is presented through …

Abivax SA Sponsored ADR $ABVX Shares Sold by Vivo Capital LLC

Vivo Capital LLC significantly reduced its stake in Abivax SA (ABVX) by 33.3% in the first quarter, selling 119,766 shares, though Abivax remains a substantial holding for the firm. Despite this sale, Abivax's stock rose by 4.6% to $124.33, and the company exceeded analyst …

Why is Abivax stock climbing today?

Abivax stock rose 3.7% after the company successfully completed a pre-New Drug Application meeting with the U.S. FDA for its ulcerative colitis treatment candidate, obefazimod. The FDA confirmed alignment on the NDA submission strategy, clearing a significant procedural hurdle. This positive development, coupled with …

Abivax on Track for 2026-end New Drug Application for Ulcerative Colitis Drug

Abivax is progressing towards a New Drug Application (NDA) by the end of 2026 for its ulcerative colitis drug. This development indicates the company's commitment to bringing its treatment to market, pending successful clinical trials and regulatory approval. The timeline suggests a focused effort …

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod

Abivax announced a positive pre-New Drug Application (NDA) interaction with the U.S. Food and Drug Administration (FDA) for obefazimod, an investigational treatment for moderately to severely active ulcerative colitis. The company confirmed alignment with the FDA on its NDA submission strategy and remains on …

Abivax completes pre-NDA meeting with FDA for obefazimod

Abivax announced the completion of its pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) for obefazimod, a treatment for ulcerative colitis. The company confirmed alignment with the FDA on its NDA submission strategy and aims to submit the NDA …

Abivax SA Sponsored ADR Revenue Breakdown – FWB:2X10

This article provides financial information for Abivax SA Sponsored ADR under the FWB:2X10 ticker on the Frankfurt Stock Exchange. It indicates that the market is currently closed with no trades. The content primarily outlines the availability of various financial data and tools on the …

Eversept Partners LP Has $104.05 Million Holdings in Abivax SA Sponsored ADR $ABVX

Eversept Partners LP significantly increased its stake in Abivax SA, acquiring an additional 276,589 shares in the first quarter, bringing its total holdings to 934,423 shares valued at approximately $104.05 million. This makes Abivax the firm's second-largest holding, representing about 5.5% of its portfolio. …

Abivax SA Sponsored ADR $ABVX Shares Sold by Octagon Capital Advisors LP

Octagon Capital Advisors LP significantly reduced its stake in Abivax SA, selling 79,000 shares and retaining 677,000 shares valued at $75.4 million, though Abivax remains a major holding for the fund. Despite this sale, institutional ownership in Abivax remains high at 47.91%, with several …

Abivax (ENXTPA:ABVX) Stock May Look Expensive Despite Leadership Appointments

Abivax (ENXTPA:ABVX) has achieved significant three-year returns, but its stock appears expensive based on market multiples and valuation checks. Despite recent leadership appointments ahead of a planned U.S. New Drug Application filing for obefazimod, the company's high price-to-book ratio (22.6x against an industry average …

Caxton Associates LLP Acquires Shares of 24,750 Abivax SA Sponsored ADR $ABVX

Caxton Associates LLP has acquired 24,750 shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) for approximately $2.76 million during the first quarter, indicating strong institutional interest in the biopharmaceutical company. Abivax currently holds a "Moderate Buy" consensus rating from analysts, with an average target price …

Affinity Asset Advisors LLC Has $45.10 Million Stake in Abivax SA Sponsored ADR $ABVX

Affinity Asset Advisors LLC recently reduced its stake in Abivax SA Sponsored ADR (ABVX) by 19.8% but still holds 405,000 shares valued at approximately $45.1 million, making it a significant position in their portfolio. Other major institutional investors like TCG Crossover Management and UBS …

Abivax SA Sponsored ADR Revenue Breakdown – SWB:2X10

This article provides a financial overview of Abivax SA Sponsored ADR (SWB:2X10) listed on the Stuttgart Stock Exchange. It highlights the availability of financial data, statements, statistics, dividends, earnings, and segment performance. The content is primarily a navigation hub for financial information on TradingView …

Abivax (ENXTPA:ABVX) Adds Commercial Leaders And Signs Valerio R And D Deal

Abivax (ENXTPA:ABVX) has expanded its commercial leadership team to prepare for the potential U.S. commercialization of its drug obefazimod and has signed an exclusive worldwide R&D collaboration with Valerio Therapeutics. These strategic moves aim to strengthen Abivax's market presence in immune-mediated inflammatory diseases and …

Abivax SA Stock 12‑Month Price Target Raised to $162.06, Implies 24% Upside

Abivax SA's average 12-month price target has been increased to $162.06 by 18 analysts, suggesting a 24% potential upside from its July 23 closing price. The target range is between $79.75 and $205.79 per share, and the consensus rating remains a "Buy" with 16 …

Abivax SA Sponsored ADR $ABVX Position Increased by PSquared Asset Management AG

PSquared Asset Management AG significantly increased its stake in Abivax SA Sponsored ADR (ABVX) by 6,650% in the first quarter, now holding 16,200 shares valued at $1.8 million. Other institutional investors also boosted their positions. This comes as Abivax reported better-than-expected quarterly earnings, and …

Morgan Stanley Adjusts Price Target on Abivax to $180 From $132, Maintains Overweight Rating

Morgan Stanley has raised its price target for Abivax (ABVX) shares to $180 from $132, while reiterating an Overweight rating on the biotechnology company. This adjustment reflects continued positive sentiment from the analyst firm regarding Abivax's prospects. The article also mentions recent news about …

ABIVAX Société Anonyme (ABVX) stock price, news, quote and history

This article provides comprehensive financial information for ABIVAX Société Anonyme (ABVX), including its stock price, historical data, analyst ratings, and recent news. The company is a clinical-stage biotechnology firm focused on developing therapeutics for chronic inflammatory diseases, with its lead drug candidate, obefazimod, in …

Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments

Abivax, a clinical-stage biotechnology company, has expanded its Commercial Leadership Team with four key appointments in marketing, patient services, sales, commercial operations, and market access. These strategic hires, including James Berger, Ivan Nuñez-Pacheco, Heather Dean, and Jeff Haas, bring extensive industry experience as the …

Precision Trading with Abivax Sa (ABVX) Risk Zones

Quantitative analysis for Abivax Sa (ABVX) suggests weak near and mid-term sentiment, despite a strong long-term outlook. Support is currently being tested, with an exceptional risk-reward setup targeting a 19.3% gain against 0.3% risk. The report details position trading, momentum breakout, and risk hedging …

17,000 Shares in Abivax SA Sponsored ADR $ABVX Bought by Militia Capital Management LLC

Militia Capital Management LLC recently acquired 17,000 shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) for approximately $1.893 million in the first quarter, establishing a new position. Abivax exceeded analyst expectations in its latest quarterly earnings report, with a narrower loss per share and higher …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Abivax S.A. (ABVX) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Abivax S.A. (NASDAQ:ABVX) following a drop in stock price. This investigation comes after Abivax announced on June 2, 2026, that its Phase 3 ABTECT clinical trial for obefazimod revealed rare …

Valerio Therapeutics, Abivax Sign R&D Deal for Inflammatory Diseases' Drug Candidates

Valerio Therapeutics and Abivax have announced a research and development agreement to identify new drug candidates for inflammatory diseases. The collaboration aims to leverage the expertise of both companies to advance treatment options in this therapeutic area.

Abivax bowel-disease drug hits goals in trial, but shares plunge on safety worries

Abivax's experimental drug obefazotide met its primary and secondary endpoints in a late-stage trial for ulcerative colitis, showing significant clinical remission and endoscopic improvement. Despite the positive efficacy results, the company's shares plunged due to concerns over higher rates of infections and elevated creatine …

ABVX Stock Clocks Best Day In 11 Months On Analyst Upgrades After Fresh Data Eases Drug Safety Concerns

ABVX Prévisions - Objectif de prix pour 2027

Abivax (ABVX) Reports Q1 2026 Financial Results with Cash Runway Extending Through 2027

Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC

Abivax Shares Surge Amid Acquisition Talks